In adult patients with B-lineage ALL (B-LIN ALL), a significant proportion of cases express the CD20 antigen on more than 10% to 20% of blasts. This immunophenotypic finding defines a distinct subpopulation with specific treatment implications at the first-line level.
Clinical scenario: B-lineage acute lymphoblastic leukemia with CD20 antigen expression in >10% to 20% of blasts. Approximately 40% of adult B-LIN ALL cases present with this CD20 positivity threshold, making upfront immunophenotyping essential to guide treatment selection.
Management of this CD20-positive subgroup incorporates antigen-directed immunotherapy as a standard component. An additional targeted immunotherapy agent is specified for use under particular molecular response conditions — the complete protocol, including sequencing and response criteria, is available via the link below.
Approximately 40% of adult B-lineage (B-LIN) ALL express the CD20 antigen in >10% to 20% ALL blasts.
The concurrent use of an anti-CD20 antibody in CD20+ ALL represents SoC as well as the use of Blina in case of molecular failure.
DOI: 10.1182/blood.2023023568